Aktis Oncology, Inc. (AKTS) vs Lumexa Imaging Holdings, Inc. Common Stock (LMRI)

A side-by-side comparison of Aktis Oncology, Inc. and Lumexa Imaging Holdings, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
$962M
$18.02HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Lumexa Imaging Holdings, Inc. Common Stock logo
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$1.02B
$10.65HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT

Total return — AKTS vs LMRI

growth of $100 · dividends reinvested · last 1y
AKTS -17.3% (-17.3%/yr)LMRI -35.4% (-35.4%/yr)AKTS compounded faster over this window
406080100120140Start $100$83$65
AKTS LMRI

AKTS vs LMRI: by the numbers

  • •LMRI is the larger company ($1.02B vs $962M market cap).
  • •Both run net losses; LMRI's is the smaller (-2.66% vs -727.04% net margin).

Metrics side by side

Valuation

MetricAKTSLMRI
Forward P/EN/A16.58
P/S ratio95.660.98
P/B ratio1.981.66
EV / EBITDAN/A27.98
FCF yieldN/A3.11%

Profitability

MetricAKTSLMRI
Gross margin100.00%11.80%
Operating margin-1149.52%1.38%
Net margin-727.04%-2.66%
ROE-15.09%-4.51%
ROIC-16.54%0.86%

Go deeper

Full AKTS analysisFull LMRI analysisInteractive comparison tool

Dig into the metrics

Aktis Oncology ROELumexa Imaging Holdings, Inc. Common Stock ROEAktis Oncology operating marginLumexa Imaging Holdings, Inc. Common Stock operating marginAktis Oncology revenue growthLumexa Imaging Holdings, Inc. Common Stock revenue growthAktis Oncology free cash flowLumexa Imaging Holdings, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.